EMA Gives Positive Opinion to Gene Therapies for Stargardt Disease and Geographic Atrophy

Hope on the Horizon: Gene Therapies for Stargardt and Geographic Atrophy Receive Positive EMA Opinion

For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in gene therapy offers a beacon of hope. The European Medicines Agency (EMA) recently delivered a positive opinion for two gene therapy products, OCU410 and OCU410ST, marking a significant step forward in the development of treatments for geographic atrophy (GA) and Stargardt disease, respectively. This development is particularly relevant to the IRD community as it could accelerate the availability of innovative therapies for these sight-threatening conditions.

Key Developments from the European Medicines Agency

Biotech firm Ocugen announced that the EMA and its Committee for Advanced Therapies (CAT) provided a positive opinion for OCU410 and OCU410ST, classifying them as Advanced Therapy Medicinal Products (ATMPs). This classification is crucial because it is designed to accelerate the regulatory review timeline for these gene therapies. It also allows Ocugen to receive scientific guidance and protocol assistance from the EMA.

OCU410 is being developed to treat vision loss caused by geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). OCU410ST is aimed at treating Stargardt disease, a condition linked to ABCA4-related retinopathies. Both therapies utilize an adeno-associated virus (AAV) platform for gene delivery. According to Ocugen, preliminary 9-month data for OCU410 showed significantly slower lesion growth and clinically meaningful visual function gains in patients with GA. For OCU410ST, 6-month data from a Phase 1 clinical trial indicated slower lesion growth and clinically meaningful visual improvement in patients with Stargardt disease. The therapies are delivered via a single subretinal injection.

This positive opinion for OCU410 and OCU410ST follows a similar update from earlier in February, when the EMA granted ATMP designation to Ocugen's OCU400, a gene therapy for retinitis pigmentosa.

What This Means for Patients and Families

The ATMP classification by the EMA signifies that these gene therapies are recognized as groundbreaking treatments with the potential to address unmet medical needs. For patients with geographic atrophy and Stargardt disease, this means that the path to potential market authorization in Europe could be streamlined. While this is not an approval for treatment, it is an important regulatory milestone that brings these potential therapies closer to those who need them. The ability to receive scientific advice and protocol assistance from the EMA can help ensure a more efficient development process, potentially reducing the time it takes for these treatments to become available.

Looking Ahead

Ocugen anticipates initiating a Phase 3 clinical trial for OCU410 next year, with potential Marketing Authorisation Application and Biologics License Application filings projected for 2028. The company expressed satisfaction with the structural and functional outcomes and the safety profile observed in their studies to date. This progress underscores the ongoing commitment within the biotech industry to develop transformative treatments for inherited retinal diseases.